Brief CV:
I obtained my PhD in Biochemistry from the University of Oviedo in 2012, I joined the same year the team of Dr. Pablo V. Escribá at the University of the Balearic Islands, firstly granted by the Marathon Foundation and after 1 year, I joined Laminar Pharma. During my first years at the company, I developed my research activity in the field of proteomics, molecular biology and the search for biomarkers applied to the study of the mechanism of action of 2OHOA (LAM561), a molecule in advanced stage of development (clinical phase III), in the area of oncology. Subsequently, I focused my career towards a more translational profile, participating in and leading several research projects, some of them as principal investigator, training future scientists and obtaining both public and private funding.
Currently, I lead scientific research as CSO, I am part of the board of directors and co-lead the coordination and strategy of the company.
Abstract:
How could a small biotech company born as a spin-off of the University of the Balearic Islands have an asset in phase III? This is the story of Laminar Pharma and its path to reach the market with its first drug, LAM561.
From the early 2000, when first results in basic research showed the therapeutic potential of LAM561, the first patent, the obstacles to keep the ownership, the first and the last patient-in.
This is a path of more than 17 years that is about to achieve its goal: to reach patients
